Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of APG-157 in Head and Neck Cancer

NCT05312710
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Interventions
APG-157
Drug
Lead sponsor
Aveta Biomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT00801060
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab + FCR, FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions
pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors

NCT00003713
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
intoplicine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab, Placebo
Biological · Other
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 25, 2026, 4:59 AM EDT
Withdrawn Phase 2 Interventional

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

NCT04684979
View directory record Official record
Conditions
B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma
Interventions
Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated
Biological
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 25, 2026, 4:59 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ABBV-901, Bevacizumab, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • Valhalla, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

NCT02204098
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions
Mammaglobin-A DNA Vaccine, Optional biopsy
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1

NCT02122952
View directory record Official record
Conditions
Spinal Muscular Atrophy 1
Interventions
AVXS-101
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
Up to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Rhode Island Asthma Integrated Response Program

NCT03583814
View directory record Official record
Conditions
Asthma in Children
Interventions
CASE Program, HARP Program
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
2 Years to 12 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 25, 2026, 4:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT05606614
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
6 Years to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Active, not recruiting Phase 4 Interventional

Smoking Cessation Program in the Construction Sector

NCT06098144
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Cessation, Tobacco Smoking
Interventions
Nicorette, Tobacco Quit-line, Brief Behavioral Counseling, Intensive Behavioral Counseling
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Antibiotic Study for Dental Implants

NCT00662532
View directory record Official record
Conditions
Periodontitis
Interventions
Minocycline HCl
Drug
Lead sponsor
OraPharma
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Hazlet, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 25, 2026, 4:59 AM EDT
Recruiting Phase 1 Interventional

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

NCT05238792
View directory record Official record
Conditions
Solid Tumor
Interventions
Tumor-associated antigen-specific T cell (TAA-T)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis

NCT03123809
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Electrical Stimulation (GES) System
Device
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 25, 2026, 4:59 AM EDT
Not listed Phase 4 Interventional

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

NCT00852787
View directory record Official record
Conditions
Hypertension, Hemodialysis
Interventions
Digoxin immune fab, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 25, 2026, 4:59 AM EDT
Completed No phase listed Observational

Imaging Modalities in Detection of Coronary Artery Disease in End-stage Renal Disease Patients

NCT00726921
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction, Stroke, Death
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

NCT00215930
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Vinorelbine, Docetaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 25, 2026, 4:59 AM EDT
Recruiting Not applicable Interventional

Readiness and Progress in Emotion Regulation Therapy

NCT07478393
View directory record Official record
Conditions
Rumination, Worry, Self-Criticism, Anxiety, Depression, Distress, Emotional
Interventions
Emotion Regulation Therapy via Telehealth
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

NCT06869187
View directory record Official record
Conditions
Bipolar Disorder Depression
Interventions
ABX-002
Drug
Lead sponsor
Autobahn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
14
States / cities
Walnut Creek, California • Cromwell, Connecticut • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 4:59 AM EDT
Withdrawn Phase 2 Interventional

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

NCT00814593
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
Biological · Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 25, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

NCT01454076
View directory record Official record
Conditions
Nonhematologic Malignancies, Lymphoma
Interventions
Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 25, 2026, 4:59 AM EDT